Clearside Biomedical IncQ) expected to post a loss of 10 cents a share - Earnings Preview
Clearside Biomedical IncQ) is anticipated to report a loss of 10 cents per share for the quarter ending June 30, 2025, despite an expected revenue increase of 88.9% to $170,000. The average analyst rating is "hold," with a median 12-month price target of $5.00, significantly above its last closing price of $0.38. The earnings estimates have remained unchanged over the last three months, with a breakdown of recommendations showing 1 strong buy, 6 holds, and no sells.
- Clearside Biomedical Inc (CLSD.OQ) (CLSD.O) is expected to
show a rise in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025
- The Alpharetta Georgia-based company is expected to report a 88.9% increase in revenue to $170 thousand from $90 thousand a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
- LSEG’s mean analyst estimate for Clearside Biomedical Inc is for a loss of 10 cents per share.
- The current average analyst rating on the shares is “hold” and the breakdown of recommendations is 1 “strong buy” or “buy,” 6 “hold” and no “sell” or “strong sell.”
- The mean earnings estimate of analysts was unchanged in the last three months.
- Wall Street’s median 12-month price target for Clearside Biomedical Inc is $5.00, about 92.3% above its last closing price of $0.38 Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2025 -0.11 -0.11 -0.11 Met -1.3
Dec. 31 2025 -0.04 -0.10 -0.10 Met -2.9
Sep. 30 2024 -0.12 -0.12 -0.10 Beat 19.5
Jun. 30 2024 -0.13 -0.13 -0.10 Beat 25.9
Mar. -0.14 -0.14 -0.15 Missed -9
31 2024
Dec. 31 2023 -0.08 -0.09 -0.08 Beat 8.6
Sep. 30 2023 -0.16 -0.15 -0.15 Met 3.2
Jun. 30 2023 -0.14 -0.14 -0.15 Missed -5.9
This summary was machine generated August 8 at 12:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
